PT-141 10mg
PT-141 (Bremelanotide) is a cyclic melanocortin peptide that acts on MC3R and MC4R receptors in the CNS. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is the only sexual dysfunction treatment that works through central nervous system melanocortin pathways rather than vascular mechanisms.
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Market avg: $54.99 — save 36%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-PT141-2026-001
Purity
99.2%
Method
HPLC-MS
Batch
PT141-2026-01A
Test Date
February 1, 2026
Identity
Confirmed
Endotoxin
<0.5 EU/mg
Storage Requirements
Lyophilized
Room temperature (15-25°C), protect from light
Reconstituted
2-8°C, use within 21 days
Cyclic melanocortin peptide. FDA-approved as Vyleesi. Very stable.
Published Research
2 peer-reviewed studies
An evaluation of bremelanotide, a novel treatment for erectile dysfunction
Diamond LE, Earle DC, Rosen RC, et al. — Journal of Sexual Medicine, 2004
Clinical evaluation of PT-141 for erectile dysfunction via melanocortin receptor activation.
Bremelanotide for hypoactive sexual desire disorder in premenopausal women
Kingsberg SA, Clayton AH, Portman D, et al. — Obstetrics & Gynecology, 2019
Phase 3 RECONNECT trials leading to FDA approval of bremelanotide.
Related Products
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.